1-(2-THIAZOLYLAZO)-2-NAPHTHOL manufacturers
- ERGi-USU
-
- $41.00 / 100mg
-
2026-01-05
- CAS:1147-56-4
- Min. Order:
- Purity: 99.28%
- Supply Ability: 10g
|
| | 1-(2-THIAZOLYLAZO)-2-NAPHTHOL Basic information |
| | 1-(2-THIAZOLYLAZO)-2-NAPHTHOL Chemical Properties |
| Melting point | 138-139 °C | | Boiling point | 464.8±47.0 °C(Predicted) | | density | 1.40 | | storage temp. | 2-8°C | | solubility | methanol: 10 mg/mL, clear | | pka | 8.71±0.50(Predicted) | | form | solid | | color | Red or orange | | BRN | 223783 | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. | | InChI | 1S/C13H9N3OS/c17-11-6-5-9-3-1-2-4-10(9)12(11)15-16-13-14-7-8-18-13/h1-8,17H | | InChIKey | IOMXCGDXEUDZAK-UHFFFAOYSA-N | | SMILES | [s]1c(ncc1)N=Nc2c3c(ccc2O)cccc3 | | CAS DataBase Reference | 1147-56-4(CAS DataBase Reference) | | EPA Substance Registry System | 2-Naphthalenol, 1-(2-thiazolylazo)- (1147-56-4) |
| Risk Statements | 36/37/38 | | Safety Statements | 22-24/25 | | WGK Germany | 3 | | TSCA | TSCA listed | | HS Code | 2927.00.5000 | | Storage Class | 11 - Combustible Solids |
| | 1-(2-THIAZOLYLAZO)-2-NAPHTHOL Usage And Synthesis |
| Description | ERGi-USU (1147-56-4) selectively inhibits the growth of ERG-positive VCaP prostate cancer cells, COLO320 colon cancer cells, KG-1 and MOLT-4 leukemia cells with minimal effect on ERG-negative cells or normal prostate or endothelial cells (IC50 = 169 nM for cell growth and 315 nM for ERG protein in VCaP cells). It selectively inhibits the kinase RIOK2 (Kd = 200 nM) causing disruption of ribosomal biogenesis and ribosomal stress. | | Uses | 1-(2-Thiazolylazo)-2-naphthol is a high affinity Rio Kinase 2 (RIOK2) inhibitor (Kd = 200 nM). Exhibits >6-fold selectivity for RIOK2 over a panel of 456 kinases. Inhibits ERG protein and potently inhibits growth of ERG-positive VCaP prostate cancer cells in vitro (IC50 = 169 nM) but not ERG-negative cell lines. Also inhibits growth of VCaP xenografts in mice. | | in vivo | NSC139021 treatment inhibits growth of ERG-positive VCaP tumor xenografts with no apparent toxicity. Significant (P<0.05, P<0.005) inhibition of tumor growth is noted at day 26 in treatment groups indicating 44% (100 mg/kg) and 65% (150 mg/kg) reduction of tumor burden. At 100 mg/kg and 150 mg/kg, no apparent toxicity including weight loss, lethargy, diarrhea, loss of appetite, respiratory distress, or overall drug related toxicity is observed. [1]. | | storage | Store at +4°C | | References | [1] AHMED A MOHAMED. Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.[J]. Cancer research, 2018: 3659-3671. DOI:10.1158/0008-5472.can-17-2949 |
| | 1-(2-THIAZOLYLAZO)-2-NAPHTHOL Preparation Products And Raw materials |
|